Physician profile
Khalid Naseer
NPI 1851341366
$2,159.27
in general payments reported to CMS, 2019-2025
30 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $311 · 2021: $351 · 2022: $339 · 2023: $152 · 2024: $400 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $688.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $260.22 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $242.20 | 2022-2024 | |
| Intercept Pharmaceuticals, INC. | $174.18 | 2019-2023 | Ocaliva |
| Gilead Sciences, INC. | $173.28 | 2019-2025 | Livdelzi |
| Ipsen Biopharmaceuticals, INC | $149.97 | 2024 | Bylvay |
| Janssen Pharmaceuticals, INC | $122.51 | 2019-2020 | |
| Janssen Biotech, INC. | $120.23 | 2019-2023 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $117.78 | 2019-2021 | |
| Qol Medical, LLC | $111.78 | 2024 | Sucraid |
| Amgen INC. | $94.35 | 2019-2021 | |
| Celgene Corporation | $80.94 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.24 | 2020-2025 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $70.11 | 2021 | |
| Novo Nordisk INC | $54.84 | 2019-2021 | |
| Amarin Pharma, INC. | $48.91 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $33.41 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.96 | 2019 | |
| Mauna Kea Technologies, INC. | $21.96 | 2019 | |
| Daiichi Sankyo INC. | $19.08 | 2019 | |
| Vapotherm INC | $18.33 | 2019 | |
| Vifor Pharma, INC. | $17.64 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.96 | 2019 | |
| Optos, INC. | $14.85 | 2020 | |
| Alfasigma USA, INC. | $13.73 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $13.68 | 2020 | |
| Radius Health, INC. | $13.55 | 2021 | |
| Redhill Biopharma INC. | $13.17 | 2021 | |
| Allergan, INC. | $11.72 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $11.56 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Naseer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.